Detalhe da pesquisa
1.
Cichoric acid targets RANKL to inhibit osteoclastogenesis and prevent ovariectomy-induced bone loss.
Phytother Res
; 38(4): 1971-1989, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38358727
2.
Myrislignan targets extracellular signal-regulated kinase (ERK) and modulates mitochondrial function to dampen osteoclastogenesis and ovariectomy-induced osteoporosis.
J Transl Med
; 21(1): 839, 2023 11 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37993937
3.
Formulating the Li sites of Li-CoOx composites for achieving high-efficiency oxidation removal of formaldehyde over the Ag/Li-CoOx catalyst under ambient conditions.
Environ Res
; 235: 116683, 2023 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37459945
4.
UPLC/Q-TOF-MS-based metabolomics evaluate the efficacy of oroxylin A against postmenopausal osteoporosis.
Biomed Chromatogr
; 37(5): e5609, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-36811170
5.
Alpinetin ameliorates bone loss in LPS-induced inflammation osteolysis via ROS mediated P38/PI3K signaling pathway.
Pharmacol Res
; 184: 106400, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35988868
6.
Periplogenin attenuates LPS-mediated inflammatory osteolysis through the suppression of osteoclastogenesis via reducing the NF-κB and MAPK signaling pathways.
Cell Death Discov
; 10(1): 86, 2024 Feb 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38368392
7.
Hecogenin alleviates LPS-induced osteolysis via regulating pyroptosis and ROS involved Nrf2 activation.
Biomed Pharmacother
; 177: 116933, 2024 Jun 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38901204
8.
Pharmacology-based molecular docking of 4-methylcatechol and its role in RANKL-mediated ROS/Keap1/Nrf2 signalling axis and osteoclastogenesis.
Biomed Pharmacother
; 159: 114101, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36640671
9.
Ethyl caffeate inhibits macrophage polarization via SIRT1/NF-κB to attenuate traumatic heterotopic ossification in mice.
Biomed Pharmacother
; 161: 114508, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37002582
10.
Casticin suppresses RANKLinduced osteoclastogenesis and prevents ovariectomyinduced bone loss by regulating the AKT/ERK and NFκB signaling pathways.
Int J Mol Med
; 51(5)2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37052260
11.
Tussilagone inhibits osteoclastogenesis by modulating mitochondrial function and ROS production involved Nrf2 activation.
Biochem Pharmacol
; 218: 115895, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38084677
12.
Isosinensetin alleviates estrogen deficiency-induced osteoporosis via suppressing ROS-mediated NF-κB/MAPK signaling pathways.
Biomed Pharmacother
; 160: 114347, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36746095
13.
Epoxymicheliolide inhibits osteoclastogenesis and resists OVX-induced osteoporosis by suppressing ERK1/2 and NFATc1 signaling.
Int Immunopharmacol
; 107: 108632, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35248947
14.
Lonafarnib Inhibits Farnesyltransferase via Suppressing ERK Signaling Pathway to Prevent Osteoclastogenesis in Titanium Particle-Induced Osteolysis.
Front Pharmacol
; 13: 848152, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35300293
15.
Oroxylin A reduces osteoclast formation and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation.
Biochem Pharmacol
; 193: 114761, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34492273